Cutera, Inc. (NASDAQ:CUTR) Director David B. Apfelberg sold 1,000 shares of the company’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $39.90, for a total value of $39,900.00. Following the completion of the transaction, the director now directly owns 10,259 shares in the company, valued at $409,334.10. The sale was disclosed in a filing with the SEC, which is available through this link.
David B. Apfelberg also recently made the following trade(s):
- On Monday, September 18th, David B. Apfelberg sold 1,000 shares of Cutera stock. The stock was sold at an average price of $38.45, for a total value of $38,450.00.
Cutera, Inc. (CUTR) traded up 2.26% during mid-day trading on Friday, hitting $38.45. The stock had a trading volume of 126,514 shares. Cutera, Inc. has a 52 week low of $12.45 and a 52 week high of $44.40. The stock has a market capitalization of $538.49 million, a P/E ratio of 82.69 and a beta of 0.53. The company’s 50 day moving average is $40.46 and its 200-day moving average is $28.85.
Cutera (NASDAQ:CUTR) last released its quarterly earnings data on Monday, August 7th. The medical device company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.10. Cutera had a return on equity of 11.64% and a net margin of 5.07%. The company had revenue of $36.40 million for the quarter, compared to analyst estimates of $32.08 million. During the same period in the previous year, the company posted $0.07 EPS. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. On average, analysts expect that Cutera, Inc. will post $0.52 EPS for the current fiscal year.
Cutera announced that its board has initiated a share repurchase plan on Monday, August 7th that authorizes the company to buyback $25.00 million in outstanding shares. This buyback authorization authorizes the medical device company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “Cutera, Inc. (CUTR) Director David B. Apfelberg Sells 1,000 Shares” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/10/20/cutera-inc-cutr-director-david-b-apfelberg-sells-1000-shares.html.
Several large investors have recently added to or reduced their stakes in CUTR. American International Group Inc. raised its stake in shares of Cutera by 7.0% during the 1st quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock valued at $149,000 after purchasing an additional 475 shares during the period. Nationwide Fund Advisors raised its stake in shares of Cutera by 8.4% during the 2nd quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock valued at $187,000 after purchasing an additional 561 shares during the period. Metropolitan Life Insurance Co. NY bought a new stake in shares of Cutera during the 1st quarter valued at $202,000. Cubist Systematic Strategies LLC bought a new stake in shares of Cutera during the 2nd quarter valued at $225,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Cutera during the 2nd quarter valued at $241,000. Institutional investors own 89.15% of the company’s stock.
Several analysts have recently issued reports on the company. Zacks Investment Research lowered Cutera from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Roth Capital increased their target price on Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a report on Tuesday, September 12th. Maxim Group lowered Cutera from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Finally, TheStreet raised Cutera from a “c” rating to a “b” rating in a report on Friday, August 18th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Cutera has an average rating of “Buy” and an average price target of $37.33.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.